Google AI helps repurpose FDA-approved drugs for Chagas disease via AlphaFold screening

AlphaFold enables rapid Chagas drug repurposing

On 12 October 2026, Google published an overview of its health AI research portfolio, highlighting a collaboration with the Institute for Global Health in Barcelona. Researchers used AlphaFold to virtually screen 30,000 compounds for antiparasitic activity against Chagas disease, a neglected tropical illness affecting roughly 8 million people that can lead to life-threatening complications if untreated. The screen identified two FDA-approved drugs that could be repurposed for Chagas, significantly expediting time-to-treatment compared to de novo drug development.

Five-year portfolio: 90 papers, 90,000+ citations

Google's health AI efforts span fundamental cellular discovery, laboratory analysis, and patient impact. Over the last five years, Google teams have published 90 peer-reviewed papers about understanding and addressing diseases, accumulating more than 90,000 citations. The work builds on Google's vision for how technology can accelerate science to improve lives, with collaborations across clinicians, academic institutes, and researchers to ensure discoveries translate from lab to patient benefit.

Key areas include:

• Accelerating drug discovery: The Chagas screening exemplifies structure-based virtual screening at scale.
• Disease detection and prevention: AI models for earlier detection of conditions from imaging, genomics, and wearable data.
• Fundamental biology: Protein structure prediction (AlphaFold), cellular modeling, and systems biology.

Collaborative research, not a product launch

The Chagas finding is a research collaboration, not a Google product or clinical recommendation. The two identified drugs require clinical validation before any treatment use. Google's role is providing AI infrastructure (AlphaFold, compute) and research partnership; the Institute for Global Health leads the biological validation. Google Health AI tools are not regulated medical devices unless separately cleared.

Researchers and pharma should track AI-accelerated screening pipelines

Drug discovery teams should evaluate AlphaFold-based virtual screening for neglected diseases and repurposing candidates. The 30,000-compound screen demonstrates throughput that traditional wet-lab HTS cannot match. Academic labs and nonprofits tackling neglected tropical diseases can access AlphaFold via Google's research partnerships or open-weight models.